Cagrilintide is a medicine that mimics a hormone called amylin that Novo Nordisk is testing in combination with semaglutide which mimics another hormone, called GLP-1 in large trials in both diabetes and weight loss, calling the combination CagriSema
Together, we will embark on a journey towards a healthier, happier you
As patients lose significant body weight on semaglutide, multiple cardiovascular parameters improve, including blood pressure, lipid profiles, and inflammatory markers
Our findings show that in the future, GLP-1 targeting medications could provide a much-needed treatment option for patients with heart failure, Krger said
That gives both you and your provider a clear picture